The estimated Net Worth of Edward J Sitar is at least $416 Thousand dollars as of 14 September 2021. Mr Sitar owns over 15,000 units of 9 Meters Biopharma stock worth over $13,604 and over the last 10 years he sold NMTR stock worth over $5,199. In addition, he makes $397,400 as Chief Financial Officer at 9 Meters Biopharma.
Mr has made over 8 trades of the 9 Meters Biopharma stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of NMTR stock worth $18,300 on 14 September 2021.
The largest trade he's ever made was buying 61,538 units of 9 Meters Biopharma stock on 15 December 2020 worth over $40,000. On average, Mr trades about 8,081 units every 157 days since 2014. As of 14 September 2021 he still owns at least 194,338 units of 9 Meters Biopharma stock.
You can see the complete history of Mr Sitar stock trades at the bottom of the page.
Edward J. Sitar CPA, CPA is the Chief Financial Officer at 9 Meters Biopharma.
As the Chief Financial Officer of 9 Meters Biopharma, the total compensation of Mr CPA at 9 Meters Biopharma is $397,400. There are 2 executives at 9 Meters Biopharma getting paid more, with John Temperato having the highest compensation of $652,437.
Mr CPA is 58, he's been the Chief Financial Officer of 9 Meters Biopharma since . There are 1 older and 2 younger executives at 9 Meters Biopharma. The oldest executive at 9 Meters Biopharma, Inc. is Dr. Patrick H. Griffin, 66, who is the Chief Medical Officer.
Edward's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT RD, STE 120, RALEIGH, NC, 27615.
Over the last 4 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, and John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
9 Meters Biopharma executives and other stock owners filed with the SEC include: